News

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA issues new share options to management

(Oslo, 15. 05.2014) Bionor Pharma ASA (OSE: BIONOR) announced today that as part of the incentive system Bionor Pharma ASA has granted a total of 1.3 million new share options to the executive management and senior management.

The share options can be issued according to the power of attorney from the General Meeting on 14 May 2014 to issue up to 12 million options to management as part of the incentive system. The total number of outstanding share options in Bionor Pharma is now 7.78 million.

All options are exercisable at yesterday’s closing price of NOK 2.55 per share. All options vest by 1/3 at 1. June 2015, 1/3 at 1. June 2016 and 1/3 at 1. June 2017.

Of the1.3 million granted new share options primary insiders were granted 1.25 million new share options as follows. 

Anker Lundemose, President and CEO at Bionor Pharma, has been granted 750 000 share options in Bionor Pharma. Options can be exercised from the day all options are vested and until 14 May 2024. Following the receipt of the options, Anker Lundemose holds 100 000 shares and 1.75 million share options in Bionor Pharma.

The remaining granted options can be exercised from the day all options are vested and until 48 months after the options have been vested.

Synne H. Røine, CFO at Bionor Pharma, has been granted 250 000 share options in Bionor Pharma.  Following the receipt of the options, Synne H. Røine holds 25 000 shares and 1.25 million share options in Bionor Pharma.

Gunnar Flåten, SVP Finance & Administration at Bionor Pharma, has been granted 100 000 share options in Bionor Pharma. Following the receipt of the options, Gunnar Flåten holds 817 500 shares and 0.9 million share options in Bionor Pharma.

Maja Sommerfelt Grønvold, CSO at Bionor Pharma, has been granted 100 000 share options in Bionor Pharma. Following the receipt of the options, Maja Sommerfelt Grønvold holds 319 287 shares and 0.9 million share options in Bionor Pharma.

Arnt Ove Hovden, Director of Viral Immunology at Bionor Pharma, has been granted 50 000 share options in Bionor Pharma. Following the receipt of the options, Arnt Ove Hovden holds 0 shares and 250 000 share options in Bionor Pharma.